18
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      HDL cholesterol, apolipoproteins, and cardiovascular risk in hemodialysis patients.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          High concentrations of HDL cholesterol are considered to indicate efficient reverse cholesterol transport and to protect from atherosclerosis. However, HDL has been suggested to be dysfunctional in ESRD. Hence, our main objective was to investigate the effect of HDL cholesterol on outcomes in maintenance hemodialysis patients with diabetes. Moreover, we investigated the associations between the major protein components of HDL (apoA1, apoA2, and apoC3) and end points. We performed an exploratory, post hoc analysis with 1255 participants (677 men and 578 women) of the German Diabetes Dialysis study. The mean age was 66.3 years and the mean body mass index was 28.0 kg/m(2). The primary end point was a composite of cardiac death, myocardial infarction, and stroke. The secondary end point included all-cause mortality. The mean duration of follow-up was 3.9 years. A total of 31.3% of the study participants reached the primary end point and 49.1% died from any cause. HDL cholesterol and apoA1 and apoC3 quartiles were not related to end points. However, there was a trend toward an inverse association between apoA2 and all-cause mortality. The hazard ratio for death from any cause in the fourth quartile compared with the first quartile of apoA2 was 0.63 (95% confidence interval, 0.40 to 0.89). The lack of an association between HDL cholesterol and cardiovascular risk may support the concept of dysfunctional HDL in hemodialysis. The possible beneficial effect of apoA2 on survival requires confirmation in future studies.

          Related collections

          Author and article information

          Journal
          J. Am. Soc. Nephrol.
          Journal of the American Society of Nephrology : JASN
          American Society of Nephrology (ASN)
          1533-3450
          1046-6673
          Feb 2015
          : 26
          : 2
          Affiliations
          [1 ] Department of Angiology, Swiss Cardiovascular Center, Inselspital, University of Bern, Bern, Switzerland; guenther.silbernagel@insel.ch.
          [2 ] Mannheim Institute of Public Health, Social and Preventive Medicine, and Institute of Public Health, Federal University of Bahia, Salvador, Brazil; Division of Nephrology, Department of Medicine I, and.
          [3 ] Division of Nephrology, Department of Medicine I, and Comprehensive Heart Failure Centre, University of Würzburg, Würzburg, Germany;
          [4 ] Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria;
          [5 ] Mannheim Institute of Public Health, Social and Preventive Medicine, and.
          [6 ] Division of Nephrology, Department of Internal Medicine, University of Heidelberg, Heidelberg, Germany; and.
          [7 ] Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria; Medical Clinic V (Nephrology, Hypertensiology, Endocrinology, Diabetology, Rheumatology), Department of Internal Medicine, Mannheim Medical Faculty, University of Heidelberg, Mannheim, Germany; Synlab Academy, Synlab Services LLC, Mannheim, Germany.
          Article
          ASN.2013080816
          10.1681/ASN.2013080816
          4310646
          25012163
          9a8f4169-fc9f-4fc2-b32c-b4ba49d1699b
          History

          cardiovascular disease,chronic dialysis,lipids,mortality risk

          Comments

          Comment on this article